Pfizer: gets new EU marketing approval for Xeljanz
(CercleFinance.com) - Pfizer has received marketing authorization from the European Commission for Xeljanz for the treatment of moderate-to-severe active ulcerative colitis, it said on Wednesday.
Xeljanz had already been approved in the EU for the treatment of moderate-to-severe active rheumatoid arthritis and for the treatment of active psoriatic arthritis in adult patients.
A chronic disease, ulcerative colitis is an inflammatory bowel disease that affects approximately 2.1 million people in Europe, whose symptoms include chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Xeljanz had already been approved in the EU for the treatment of moderate-to-severe active rheumatoid arthritis and for the treatment of active psoriatic arthritis in adult patients.
A chronic disease, ulcerative colitis is an inflammatory bowel disease that affects approximately 2.1 million people in Europe, whose symptoms include chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss.
Copyright (c) 2018 CercleFinance.com. All rights reserved.